MLTX - MoonLake Immunotherapeutics
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis.
As of Nov 13, 2026: spot at $12.61, ATM IV 105.4%, max pain $11.00, GEX (assumed dealer book) $41.2K of delta per 1% move.
Exposures are the assumed dealer book over the expirations within 30 days of the session, or the first four when none are (1 expiration, through Nov 20, 2026), as of Nov 13, 2026. Assumes dealers are long the calls and short the puts, a share p of open interest each - here 100% of open interest (the GEX page sets the share). A date without a stored exposure is a gap; a value marked * is partial, averaged over fewer days, or may include contracts expiring that day or of an unreadable expiration: its reason is printed beside it.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $1.06B
- Beta
- 1.13
- 52-Week Range
- 9.46-23.29
- CEO
- Jorge Santos da Silva
- Employees
- 130
- IPO Date
- Oct 20, 2020
- Exchange
- NASDAQ
What MLTX Looks Like to Options Traders Today
IV rank of 27.3% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); the assumed dealer book's GEX is positive ($41.2K of delta per 1% move): its hedging leans against the trend, damping realized volatility where real dealers are positioned like the book; the 25-delta skew (0.389) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The MLTX overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked MLTX overview questions
- What is MLTX?
- MLTX is the ticker symbol for MoonLake Immunotherapeutics, a listed security. MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Listed on NASDAQ. MLTX is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the MLTX options snapshot look like today?
- As of Nov 13, 2026, the MLTX options snapshot shows spot at $12.61, ATM IV 105.4%, IV rank 27.3%, max pain $11.00, GEX (assumed dealer book) $41.2K of delta per 1% move, expected move 30.22%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, the assumed dealer book's gamma exposure and the put-minus-call delta balance, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are MLTX's key statistics?
- MoonLake Immunotherapeutics (MLTX) carries a market capitalization of $1.06B, beta of 1.13 relative to the broader market, 52-week range of 9.46-23.29. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does MLTX belong to?
- MoonLake Immunotherapeutics operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare MLTX's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the MLTX data on this page?
- The options snapshot above is dated Nov 13, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, twice-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).